Peptonic Medical AB (publ) (“Peptonic” or the “Company”) provides clarifying information in connection with the press release published on 2 September 2026 regarding the Company’s
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has today, 2 September 2026, acquired 2,776,673 shares in DGH International AB (“DGH”). The acquisition is financed
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has today, 2 September 2026, acquired 2,776,673 shares in DGH International AB (“DGH”). The acquisition is financed
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has received a new order under the Company’s partnership agreement with an established US player in intimate
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) publishes today, August 19, 2026, financial report for the second quarter 2026. Key figures for the Group
Peptonic Medical AB (publ) (“Peptonic”) announces that board member Tarek Shoeb is leaving the board at his own request. Tarek Shoeb has today, Tuesday, August
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) today publishes its Annual Report and Consolidated Financial Statements, together with the Auditor’s Report, for the 2025
Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces a regulatory update regarding Vernivia®. The Company has now finalised the relevant interim reports with its
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) publishes today, February 27, 2026, its year-end report for 2025. Key figures for the Group – Fourth
Peptonic Medical AB (publ) (“Peptonic”) announces the appointment of Daniel Rudeklint as interim CEO with immediate effect. Daniel Rudeklint replaces Anna Linton as CEO. Daniel
Peptonic Medical AB (publ) (the “Company”) announces that the Company has terminated its agreement with Mangold Fondförvaltning AB regarding the assignment as liquidity provider. The
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“the Company”) announces a changed date for the publication of the Q4 report and also the year-end report for 2025 from
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Company’s reconstruction plan, which was confirmed by the Uppsala District Court on 28 November
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) clarifies the next steps in the reconstruction process and when the Company’s corporate reconstruction is expected to
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court has decided to approve the Company’s reconstruction plan. The court’s decision
Peptonic Medical AB (publ) (“the Company”) announces that a plan hearing was held today at Uppsala District Court. During the hearing, the reconstruction plan was
Peptonic Medical AB (publ) (“the Company”) announces current sales figures in connection with the plan hearing being held today at 10:00 AM at the Uppsala
The press release announced today at 13:00 CET was referring to a previous press release that Uppsala District Court has approved the Company’s request to
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court today, on 19 September 2025, has approved the Company’s request to
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has received part of the first order under the recently signed strategic distribution agreement with US-based Joylux
Peptonic Medical AB (publ) (“the Company” or “Peptonic”) announces that the plan meeting in the Company’s corporate reorganization will be held on 27 November 2025
Peptonic Medical AB (publ) (the “Company”) announces the reconstruction plan in the Company’s ongoing corporate restructuring (the “Reconstruction Plan”). The Reconstruction Plan has today been
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has entered into a strategic distribution agreement with Joylux Inc., a well-established provider of intimate wellness solutions
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court today, on 19 September 2025, has approved the Company’s request to
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has today submitted a request to the Uppsala District Court to extend the ongoing corporate reconstruction by
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) today announces that Anna Linton, at her own request, resigns from her role as Chief Executive Officer.
On 23 May 2025, PEPTONIC medical AB (“Peptonic” or the “Company”) issued a notice to the annual general meeting to be held on 26 June
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court has today, June 17 2025, approved the Company’s request to extend
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has today submitted a request to the Uppsala District Court to extend the ongoing company reconstruction by
In Peptonic Medical’s annual report for 2024, there was a remark in the audit report: “We draw attention to the administration report, which states that
The 2024 Annual report of Peptonic Medical AB (publ) is now available on the company website. The annual report is available in Swedish in PDF
PEPTONIC medical AB (publ) (the “Company”) has, as previously communicated, applied for and been granted corporate restructuring by the Uppsala District Court. At the creditors’
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting in PEPTONIC medical AB,
Correction of the press release published on 7 May 2025 regarding the resolution from the extraordinary general meeting on 7 January 2025 on the reduction
As communicated in the notice to the extraordinary general meeting on 28 November 2024, two proposals were submitted for a reduction of the share capital
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
As communicated through a press release on March 11, 2025, the board of directors of PEPTONIC Medical AB (publ) (the “Company”) decided to submit an
As part of its growth strategy in the US market, Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has established a new wholly-owned subsidiary, Peptonic
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the press release issued on March 14, 2025, titled “Court of Appeal convicts former employees
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Court of Appeal has overturned the District Court’s acquittal in the insider trading case
Peptonic Medical AB (publ.) (“Peptonic” or “the Company”) announces that the Uppsala District Court has approved the Company’s application for corporate restructuring. This decision enables
The Board of Directors of Peptonic Medical AB (publ.) (“Peptonic” or “the Company”) has today decided to submit an application for corporate restructuring. This decision
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) is adjusting its organization following the structural changes implemented in 2024. As part of this process, the
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic” or “the Company”) is thrilled to announce the highly anticipated U.S. launch of its portfolio of intimate care products under
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical (publ) (“Peptonic” or “the Company”) has had a highly successful launch of VagiVital Intimate Calming Gel in Sweden, with nearly 1,000 units sold
Peptonic Medical (publ) (“Peptonic” or “the Company”) announces the launch of VagiVital Intimate Calming Gel, a specially developed product that provides immediate moisture while relieving
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces the successful launch of its in-house developed lubricant, VagiVital Active Glide, at the turn of the
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent for the relief
The extraordinary general meeting of PEPTONIC medical AB, reg. no. 556776-3064 (the “Company”), was held today on 7 January 2025. The meeting resolved, with the
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in PEPTONIC medical AB,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Today, Peptonic Medical AB (“Peptonic”) publishes an operational update outlining the strategic actions and initiatives implemented and planned for the year. These efforts are expected
Peptonic Medical AB (“Peptonic”) today announces its decision to discontinue its Israeli subsidiary, a contract manufacturing organization (CMO) specializing in self-diagnostic tests. The decision will
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) is taking a crucial step to establish its VagiVital brand in the U.S. market and drive sales growth of its
Peptonic Medical (publ) (“Peptonic”) is further strengthening its product portfolio with the launch of VagiVital Intimate Calming Gel, a specially formulated product designed to provide
Peptonic Medical (publ) (“Peptonic”) is expanding its portfolio of clinically proven intimate self-care products with the launch of VagiVital Active Glide, a water-based lubricant specifically
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic”) has received notification that the Australian patent office has granted the FOAM II patent. This patent provides broad protection for
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (“Peptonic”) today presents an operational update highlighting the strategic measures implemented during Anna Linton’s first 120 days as CEO. These efforts, aimed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic”) announces that the European Patent Office (“EPO”) has granted a patent for the relief of provoked vulvodynia (previously referred to
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic”) announces today changes within its organization. Global Business Director, Erik Sundquist, and Senior Advisor, Dan Markusson, will be leaving their
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) announces the appointment of Jenni Björnulfson as the company’s new Chief Financial Officer (CFO). Jenni will assume the position on
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) announces that the United States Patent and Trademark Office (“USPTO”) has granted patent (16238.0043U1) for the treatment and prevention of
Peptonic Medical AB (publ) (“Peptonic”) has signed an exclusive distribution agreement with FirstAid4All to launch Peptonic’s products in intimate self-care in Belgium, the Netherlands, and
Peptonic Medical AB (“Peptonic”) clarifies short term strategic priorities under the leadership of its new CEO. Committed to achieving tangible results, the company is prioritizing
Peptonic Medical AB (publ) today announced the launch of two new products on the home market in Sweden: VagiVital Menopause FSH Test and VagiVital Urinary
Peptonic Medical AB (publ) (“Peptonic”) announced today that Doz Apotek will include the company’s product Vernivia against bacterial vaginosis in the assortment in 51 of
Peptonic Medical AB (publ) (“Peptonic”) is extending the partnership with Farmasiet that will bring the entire VagVital product portfolio to the Norwegian market. Farmasiet, Norway’s
Peptonic Medical AB (publ) (“Peptonic”) announced today that the company’s patented intimate wash, VagiVital Moisturizing V Cleanser, is being offered for sale in 293 Apoteket
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (”Peptonic”) today announced that the company has signed a non-exclusive distribution agreement with Al Fotune Medical Equipment LLC for United Arab Emirate concerning the product VagiVital VS Pro. ”Al Fotune is a medical device company
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) announced today that the company’s patented product for self-testing of bacterial vaginosis, VagiVital VS, is being offered for sale in
Today, November 2, 2023 the exercise period for warrants of series TO3 begins in PEPTONIC medical AB (“Peptonic” or the “Company”). The exercise period lasts
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic CEO Erik Sundquist presented the company on Biostock Life Summit Event in Lund October 26, 2023. If you were unable to see the event
Peptonic Medical AB (publ) today announced that CEO Erik Sundquist will present the company at the BioStock Life Science Fall Summit in Lund, Sweden, on
Peptonic Medical AB (publ) today announced that it has received its first order in Central America from Windsor Pharmaceuticals. “It is gratifying that Windsor now
Peptonic Medical will present at the BioStock Life Science Fall Summit in Lund on October 25-26. Join us for our presentation at 15:30 on October 26th. Read more
Peptonic Medical AB (publ) (“Peptonic”) announced today that the company has agreed with the world’s largest retail chain Walmart to begin selling Peptonic’s self-test for
Peptonic Medical AB (publ) (“Peptonic”) today announced that it has signed an exclusive agreement regarding VagiVital’s amniotic leak self-test with Savyon Diagnostics (“Savyon”) for the
At an extraordinary general meeting on August 21, Pharmiva’s shareholders approved the planned merger between Peptonic Medical AB (“Peptonic”) and Pharmiva AB (“Pharmiva”). The merger
